Contact the Editorial Desk

Editorial correspondence

Peptide Batteries welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial result, a regulatory status change, or a peer-reviewed study on GHK-Cu, MOTS-c, retatrutide, or tirzepatide that should be added to the references page. This is the most useful class of message this desk receives, and each one is read carefully.

The most actionable submissions specify the page in question, the exact passage being corrected, and a supporting reference — a DOI or PubMed identifier wherever possible — so the proposed change can be checked against its source before anything is updated.

Editorial mailbox: editors@peptidebatteries.com

What this desk cannot do

A reading bench, not a clinical service: this desk cannot advise on or recommend human use of any peptide covered here, cannot suggest a dose or administration schedule for anyone, cannot judge whether a cited trial result applies to a particular person, and cannot help source, sell, or locate any compound from any supplier. Tirzepatide is a prescription medicine available only through a licensed provider. Retatrutide is investigational and not legally available outside a registered clinical trial. GHK-Cu is a topical cosmetic ingredient, a category separate from FDA-approved drugs. MOTS-c has no FDA approval, including when supplied as a compounded prescription medication. A reader after clinical guidance should consult a licensed clinician in their own jurisdiction. Replies to editorial correspondence are not guaranteed and may be delayed.